Pasithea Therapeutics (KTTA) Other Non-Current Liabilities (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $163578.0 as the latest value for Q3 2024.
- Quarterly Other Non-Current Liabilities rose 462.92% to $163578.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $163578.0 through Sep 2024, up 462.92% year-over-year, with the annual reading at $84366.0 for FY2023, 40.0% down from the prior year.
- Other Non-Current Liabilities hit $163578.0 in Q3 2024 for Pasithea Therapeutics, up from $93272.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $4.0 million in Q3 2021 to a low of $29059.0 in Q3 2023.
- Historically, Other Non-Current Liabilities has averaged $600037.1 across 4 years, with a median of $163578.0 in 2024.
- Biggest five-year swings in Other Non-Current Liabilities: tumbled 95.0% in 2023 and later skyrocketed 462.92% in 2024.
- Year by year, Other Non-Current Liabilities stood at $1.5 million in 2021, then plummeted by 90.32% to $140611.0 in 2022, then plummeted by 40.0% to $84366.0 in 2023, then surged by 93.89% to $163578.0 in 2024.
- Business Quant data shows Other Non-Current Liabilities for KTTA at $163578.0 in Q3 2024, $93272.0 in Q2 2024, and $57650.0 in Q1 2024.